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Abstract: Pharmacogenetics and biomarkers are becoming normalised as important technologies to 16 
improve drug efficacy rates, reduce the incidence of adverse drug reactions, and make informed 17 
choices for targeted therapies. However, their wider clinical implementation has been limited by a 18 
lack of robust evidence. Suitable evidence is required before a biomarker’s clinical use, and also before 19 
its use in a clinical trial. We have undertaken a review of five pharmacogenetic biomarker-guided 20 
randomised controlled trials (RCTs) and evaluated the evidence used by these trials to justify 21 
biomarker inclusion. We assessed and quantified the evidence cited in published rationale papers, or 22 
where these were not available, obtained protocols from trial authors. Very different levels of evidence 23 
were provided by the trials. We used these observations to write recommendations for future 24 
justifications of biomarker use in RCTs and encourage regulatory authorities to write clear guidelines.  25 
 26 
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1. Introduction 29 
The growing field of pharmacogenetics, which studies the effect of genetic biomarkers on the 30 
likelihood of treatment response or adverse drug reactions (ADRs) [1], offers an important opportunity 31 
to increase the chances of drug benefit and/or reduce the risk of harm [2-5]. A biomarker is defined as 32 
“a characteristic that is objectively measured and evaluated as an indicator of normal biological 33 
processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention” [6]. Both 34 
germline and somatic genetic biomarkers are being used increasingly to personalise treatments across 35 
a wide range of disease areas, including cancer [7,8], thromboembolic disease [9], and autoimmune 36 
disease [10], as well as to diagnose disease and provide patient prognosis.  37 
Many drugs are withdrawn from the market due to lack of efficacy and/or ADRs [11-13], and the 38 
latter are a major cause of hospital admissions, morbidity, and mortality [14,15]. ADRs are associated 39 
with high cost in terms of both time and resources, as well as the negative effects on patient health. 40 
There is therefore great potential for genetic biomarker testing to improve the efficacy, safety and cost-41 
effectiveness of medicines.  Reviews of economic evaluations of medicines with actionable 42 
pharmacogenetic information found the majority of tests to be cost-effective or even cost-saving [16,17]. 43 
For example, screening for the HLA-B*57:01 allele has significantly reduced the incidence of severe 44 
ADRs associated with abacavir [18], and has been recommended as a cost-effective intervention [19]. 45 
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Although it should not be assumed that all pharmacogenetic testing will be cost-effective [20], 46 
reductions in the cost of testing and efficiency improvements may see the implementation of more 47 
pharmacogenetic tests into clinical practice.  48 
While the US Food and Drug Administration (FDA) lists over 200 drugs with pharmacogenetic 49 
information included in their labels [21], their wider clinical implementation has been limited [22-26]. 50 
There are many reasons for this, including the lack of robust evidence of clinical utility [27,28]. Prior to 51 
the approval and implementation of biomarker tests in clinical practice, evidence is required of the 52 
test’s clinical utility [29-32] and the gold-standard approach to do this according to guidelines is the 53 
randomised controlled trial (RCT) [33-35]. A lack of well-designed trials has been cited as one of the 54 
main obstacles contributing to the delay in translation of pharmacogenetic discoveries into clinic 55 
[28,30,36,37]. Several biomarker-guided trial (‘BM trial’) designs have been proposed for this purpose 56 
[38-40], and our previously developed online tool, www.bigted.org, provides information about each 57 
to guide those designing such a trial [39]. However, before embarking on a BM trial, it is important that 58 
robust evidence of the biomarker’s utility and validity is available to justify its inclusion in the trial’s 59 
design [41] – without this, there is a risk of wasting money and time on an inappropriate biomarker. 60 
Nonetheless, the nature and extent of evidence required, and how it should be compiled, is unclear. 61 
More guidance exists on the evidence required for interventions to be included in a trial than for 62 
biomarker inclusion, although an integral biomarker assay is just as important a component of the trial 63 
[41,42].  64 
With this in mind, we undertook a literature review with the aim of reviewing sources of evidence 65 
used to justify five previously published pharmacogenetic BM trials.  These were chosen to represent 66 
different pharmacogenetic biomarker applications. We explored the nature and extent of previous 67 
evidence on the association of the included biomarkers with treatment response that had been used to 68 
justify their inclusion. We were not concerned with the findings of the trials, instead focusing purely 69 
on the evidence cited to justify the inclusion of biomarker(s) within their design. Indeed, we 70 
acknowledge that other trials will have been conducted since the publication of the trials included in 71 
our review which will have added to the evidence base on the use of the drugs under study. In light of 72 
our findings, we also reflected on and provided recommendations on how such evidence should be 73 
compiled by those planning future BM trials.   74 
2. Details of included trials 75 
To allow us to explore in detail the evidence compiled for each trial, we limited our review to five 76 
recently published BM trials. These were chosen carefully to ensure that they were representative of 77 
the available trials and spanned a range of different biomarker applications. We felt it important to not 78 
only include trials using biomarkers in a way that has been well-characterised (e.g. for targeted 79 
therapies), but also those incorporating biomarkers for less well-characterised purposes (e.g. improving 80 
medication adherence). The five chosen trials used biomarkers for prevention of ADRs [10], improving 81 
efficacy [9], choosing targeted therapies [43], improving medication adherence [44,45], and improving 82 
quality of life [46].  Summary details of each trial are provided in Table 1. The first trial (TPMT: AZA 83 
Response to Genotyping and Enzyme Testing, TARGET, 2011) explored whether TPMT genotyping 84 
helped prevent ADRs associated with azathioprine [10,47].  A second trial (European Pharmacogenetics 85 
of Anticoagulant Therapy, EU-PACT, 2013) tested whether a genotype-guided approach to calculating 86 
therapeutic dose of the anticoagulant, warfarin, led to improved efficacy and reduced the incidence of 87 
ADRs [9]. The third trial (SHIVA, 2015) explored the utility of an approach that used genotyping to 88 
match patients to molecularly targeted therapies [43]. A fourth trial (Genotype-guided statin therapy, 89 
GGST statin trial, 2018) explored whether using genotype testing improved medication adherence and 90 
subsequently statin efficacy [44,45,48]. The final trial (NCT02664350) investigated the use of genotyping 91 
to reduce pain associated with cancer [46].  92 
 93 
 94 
 95 
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Table 1- details of selected trials. Start year denotes year the first patient was recruited. BM trial 99 
(biomarker-guided trial) design is the design as selected by using the BiGTeD online resource [39]. 100 
 101 
Registration 
number 
Trial 
name 
Start 
year 
Year of 
results 
publication  
Paper references taken 
from 
BM trial 
design 
Biomarker Drug of 
interest 
Sample size 
(n 
randomised) 
Age of 
participants 
Sex of 
participants 
Ethnicity of 
participants 
Study 
location 
ISRCTN30748308 
TARGET 
(protocol) 
[10,47] 
2005 2011 
2005 protocol obtained 
from authors 
Biomarker 
strategy 
design 
(without 
biomarker 
assessment 
in control 
arm) 
TPMT Azathioprine 333 
Mean 43.2 
(control)  
50.6%/49.4% 
F/M 
(control) 
92.2% 
white, 4.8% 
South 
Asian, 0.6% 
Black, 2.4% 
mixed/other 
(control) 
UK 
Mean 41.0 
(genotyped) 
50.3%/49.7% 
F/M 
(genotyped) 
89.8% 
white, 7.2% 
South 
Asian, 3.0% 
Black, 0% 
mixed/other 
(genotyped) 
NCT01119300 
EU-PACT  
[49] 
2011 2013 
2009 paper 
10.2217/pgs.09.125 
Biomarker 
strategy 
design 
(without 
biomarker 
assessment 
in control 
arm) 
CYP2C9*2 
Warfarin 455 
Mean 66.9 
(control)  
42.1%/57.9% 
F/M 
(control) 
98.7% 
white, 0.9% 
Black, 0.4% 
Asian 
(control) 
UK, 
Sweden 
CYP2C9*3 
Mean 67.8 
(genotyped) 
 
35.8%/64.2% 
F/M 
(genotyped) 
98.2% 
white, 1.3% 
Black, 0.4% 
Asian 
(genotyped) 
VKORC1       
NCT01771458 
SHIVA  
[43] 
(protocol) 
2012 2015 
2014 protocol obtained 
from authors 
Enrichment 
design 
Hormone 
receptors 
pathway 
Targeted 
chemotherapy 
agent, based 
on 
genotyping 
195 
Median 63 
(control) 
72%/28% 
F/M 
(control) 
Not 
reported 
France PI3K/AKT/mTOR 
pathway 
Median 61 
(genotyped) 
  
61%/39% 
F/M 
(genotyped) 
  
RAF/MEK 
pathway 
NCT01894230 
GGST 
statin 
trial  
[44] 
2013 2018 
2016 paper 
10.2217/pgs-2016-0065 
Biomarker 
strategy 
design 
(with 
biomarker 
SLCO1B1*5 Any statin 159 
Mean 62.5 
(control) 
65.8%/34.2% 
F/M 
(control) 
80.3% 
white, 
14.5% Black, 
5.3% other 
(control) 
USA 
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assessment 
in control 
arm) 
Mean 62.7 
(genotyped) 
49.4%/50.6% 
F/M 
(genotyped) 
79.5% 
white, 
16.9% Black, 
3.6% other 
(genotyped) 
NCT02664350 
n/a 
[46] 
2016 
Results not 
yet 
published 
2018 paper 
10.1016/j.cct.2018.03.001 
Biomarker 
strategy 
design 
(without 
biomarker 
assessment 
in control 
arm) 
CYP2D6 Opioids 
200 
(forecast) 
Not 
available 
Not 
available 
Not 
available 
USA 
 102 
For each trial, we identified each piece of evidence referenced in the introduction section of a 103 
protocol or design paper associated with the trial, and extracted details of the publication year (Figure 104 
1), study design, drug of interest, biomarker used, sample size, country of origin, and the age, sex and 105 
ethnicity of participants for each trial. For trials that did not have a published protocol or design paper, 106 
we used protocols obtained from contacting the authors (TARGET), or from the results paper 107 
supplementary information (SHIVA).  Full details of data extracted are found in Table 1. Figures were 108 
made using RStudio (version 1.1.453, RStudio Team, Boston MA) [50], particularly the ‘formattable’ 109 
package [51], and LucidChart [52]. 110 
 111 
Figure 1 - Timings of publications cited by each trial. Star icons indicate the date of publication of the 112 
paper or protocol references were extracted from. †results not yet published 113 
 114 
3. TARGET  115 
TARGET (ISRCTN30748308) began recruitment in 2005 and investigated the use of TPMT 116 
genotyping to prevent adverse reactions to azathioprine in patients with inflammatory disease [10,53]. 117 
The trial randomised inflammatory disease patients (in gastroenterology and rheumatology) 1:1 to 118 
genotyping or non-genotyping arms. In the genotyping arm, clinicians were made aware of each 119 
patient’s TPMT status and the implications of this on dosing prior to commencing azathioprine 120 
treatment. Patients in the non-genotyping arm received standard azathioprine dosing.  121 
 122 
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TARGET used a biomarker strategy design without biomarker assessment in the control arm [39],  123 
Evidence used to justify use of the genotype test spanned the longest time frame of all trials, from 1980 124 
to 2003 (Figure 2Error! Reference source not found.).  The oldest evidence cited by the trial was a 1980 125 
observational cohort study that proposed a monogenic inheritance pattern for the activity of the TPMT 126 
enzyme [54]. Also cited was a 1989 case-control study that compared TPMT enzyme activity in patients 127 
who had adverse reactions to thiopurines to a control group that had suffered no reaction [55]. The 128 
study showed that patients who had the adverse reaction had extremely low TPMT activity. In total, 129 
11 observational studies were cited, consisting of 9 cohort studies [54,56-63], 1 case control study [55], 130 
and 1 study of enzymatic assay use in the UK [64]. A 2001 systematic review of pharmacogenetics in 131 
reducing ADRs was cited, although this review was not specific to azathioprine or TPMT. 132 
 133 
 134 
Figure 2 – Evidence cited by the TARGET trial to justify inclusion of the TPMT biomarker, relative to 135 
the publication of the 2005 protocol [47]. 136 
 137 
The most recent evidence was an expert opinion by Seidman, 2003 [65].  A 2002 Canadian cost-138 
effectiveness analysis [66], a 2000 case study [67], and a 1997 questionnaire of UK clinicians were also 139 
cited [68]. The authors also cited a 2000 guideline from the British Society of Rheumatology, which 140 
could not be located online.  141 
 142 
4. EU-PACT  143 
The EU-PACT study (NCT01119300) was a large, single-blind, randomised European trial of 144 
genotype-guided dosing of warfarin [9,49,69-71]. Patients in this trial were randomised 1:1 to genotype-145 
guided or control groups, stratified by centre and treatment indication. Those in the genotype-guided 146 
group were genotyped for CYP2C9 and VKORC1 and dosed according to an algorithm that included 147 
both genetic and clinical factors. The control group received a standard dosing regimen guided by 148 
clinical factors only.  149 
 150 
This trial also used a biomarker strategy design without biomarker assessment in the control arm 151 
[39]. The published protocol cited mostly observational studies as evidence (Figure 3). These ranged 152 
from a 1992 retrospective cohort study [72] to several 2009 studies [73-75]. This includes a 2009 genome-153 
wide association study (GWAS) that showed the implications of specific CYP2C9, VKORC1, and 154 
CYP4F2 genes on warfarin dosing. Also cited were editorials [76,77], cost-effectiveness analyses [78,79], 155 
and a literature review of economic evaluations [80].  No previous RCTs were cited.  156 
 157 
Figure 3 – Evidence cited by the EU-PACT trial to justify inclusion of the CYP2C9 and VKORC1 158 
biomarkers, relative to the publication of the 2009 published protocol [49]. 159 
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5. SHIVA  161 
The SHIVA trial (NCT01771458) was a French proof-of-concept histology-agnostic phase II trial 162 
using an enrichment design [39] that recruited patients with any metastatic solid cancer to receive 163 
treatment with targeted agents [43,81,82]. After analysis of their tumour, patients with mutations that 164 
matched an available drug were randomised 1:1 to receive targeted treatment or to physician’s choice 165 
treatment. 166 
The total evidence cited in the protocol ranged from 1998 to 2011 (Figure 4). Three RCTs were cited 167 
[83-85]. Two of these were trials of gefinitib in lung cancer [83,84]. Another RCT cited was an 168 
investigation of trastuzumab in HER2+ breast cancer patients, a combination that was investigated in 169 
SHIVA [85]. Two observational studies were cited [86,87], along with a contemporaneous editorial 170 
commenting on the validity of one of these studies [88]. 171 
 172 
 173 
Figure 4 – Evidence cited by the SHIVA trial to justify inclusion of the biomarkers, relative to the 174 
publication of the 2014 protocol (included in Supplementary of a 2015 paper [43]). 175 
RCT = randomised controlled trial 176 
 177 
The paper reporting on the results of this trial included an ‘Evidence before this study’ box [43]. 178 
This detailed a literature search performed prior to the start of the trial, which identified several 179 
observational cohort studies [87,89-92] and RCTs [93-95] .  180 
 181 
6. GGST statin trial  182 
The SLCO1B1 genotype guided statin therapy (GGST) trial (NCT01894230) investigated the utility 183 
of using genotyping to increase adherence to statins and promote lower cholesterol in patients with 184 
cardiovascular disease and a history of statin-induced side effects [44,45,48]. Patients were genotyped 185 
and then randomised 1:1 to receive genotype information to guide their care, or to usual care alone. 186 
The primary outcome in this trial was medication adherence, as assessed by a standard questionnaire. 187 
The aim of the trial was to improve adherence by showing patients that treatment includes an 188 
assessment of the risks (real and perceived) of statin-induced side-effects [44]. The trial used a 189 
biomarker strategy with biomarker assessment in the control arm design [39].  190 
This trial cited a large number of references ranging from 2002 to 2015 (Figure 5). Five sets of 191 
guidelines from four separate bodies were cited [96-100], alongside an epidemiology report from the 192 
American Heart Association [101]. Seven literature reviews were cited [102-108], alongside two 193 
editorials [109,110]. This trial also cited the largest number of observational studies, a total of eleven 194 
(consisting of 1 case control study [111], 9 cohort studies [112-120], and 1 cohort/meta-analysis study 195 
[121]). In contrast to the large amount of observational study evidence, the trial only cited one RCT 196 
[122]. Two further references were sub-studies of larger RCTs [123,124]. A 2013 Cochrane review was 197 
also cited [125]. 198 
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 199 
Figure 5 – Evidence cited by the GGST statin trial to justify inclusion of the SLCO1B1 biomarker, relative 200 
to the publication of the 2016 rationale and design paper [44]. ‘Mixed’ refers to papers that used a 201 
mixture of two or more of the other publication types. RCT = randomised controlled trial 202 
SR/MAs = systematic reviews/meta-analyses 203 
 204 
The authors cited one systematic review [126] and three meta-analyses [127-129]. The systematic 205 
review [126] assessed the quality of included studies using ISPOR guidelines [130], and one meta-206 
analysis [129] evaluated quality using the Newcastle-Ottawa scale [131]. The other two meta-analyses 207 
were published by the Cholesterol Treatment Trialists’ Collaborators (CTTC) group [127,128], a group 208 
established in 1994 to perform meta-analyses of long-term and large-scale trials of lipid intervention 209 
therapies [132].  210 
The meta-analyses by the CTTC group were both done on the same large data set of n=174,149 211 
participants from 27 RCTs [127,128]. Each RCT had to have a recruitment target of >1000 participants, 212 
and have a minimum 2 year treatment duration. The meta-analyses collated individual participant data 213 
(IPD).  These meta-analyses did not assess the quality of the included studies. 214 
 215 
7. Precision Medicine Guided Treatment for Cancer Pain  216 
This trial (NCT02664350) used a biomarker strategy design without biomarker assessment in the 217 
control arm, and recruited patients with solid tumours and metastases to investigate CYP2D6-guided 218 
dosing of opioids to manage pain [46]. Patients with pain scores of ≥4 (on a scale of 1-10) were 219 
randomised 1:1 to genotype-guided or conventional pain management strategies. This trial did not 220 
assign treatments to patients, but provided recommendations to clinicians based on CYP2D6 221 
genotyping. Patients with poor metabolizer, intermediate metabolizer, or ultra-rapid metabolizer 222 
phenotypes were recommended different opioids to those with an extensive (‘normal’) metabolizer 223 
phenotype. Those in the control group did not receive CYP2D6-guided recommendations. Pain 224 
questionnaires were completed at baseline, 2, 4, 6, and 8 weeks. The trial is completed but results have 225 
not yet been published. 226 
The authors cited evidence ranging from 1998 to 2017 (Figure 6). The oldest evidence was a 1998 227 
RCT [133], cited alongside 5 other RCTs [134-138]. The newest evidence was 2017 guidelines on adult 228 
cancer pain from the National Comprehensive Cancer Network [139]. Interestingly, the trial cited three 229 
case studies; one in a patient with the poor metabolizer phenotype [140], and two with patients with 230 
the ultra-rapid metabolizer phenotype [141,142].  231 
 232 
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 233 
Figure 6 – Evidence cited by the NCT02664350 trial to justify inclusion of the CYP2D6 biomarker, 234 
relative to the publication of the 2018 design and rationale paper [46].  235 
 236 
8. Discussion 237 
The trials in our review all used different approaches to gathering evidence for justifying 238 
biomarker inclusion, and there does not appear to be a standard approach to doing so. Of the trials 239 
examined, all cited evidence from within 3 years of their publication (Figure 1).  The oldest evidence 240 
compared to trial start date was cited by the TARGET trial, which cited work from 25 years prior to its 241 
2005 start date [54]. 242 
The evidence types used included systematic reviews/meta-analyses, RCTs, qualitative research, 243 
guidelines, recommendations, editorials, and case studies. The traditional ‘evidence pyramid’ is often 244 
used to rank evidence types, with meta-analyses and systematic reviews at the top, and case studies 245 
and in vitro evidence near the base [143]. However, this has seen some modification in recent years, 246 
notably the viewing of evidence through the ‘lens’ of systematic reviews and meta-analyses, ensuring 247 
that the quality of included studies is evaluated [144]. In this iteration, a meta-analysis based on weak 248 
evidence suffering from bias is not automatically seen as superior evidence to a well-conducted 249 
observational study. 250 
To explore the type and extent of evidence compiled to justify including biomarkers in previous 251 
BM trials, we have referred to the references in the trial design paper or protocol. This represents a 252 
relatively straightforward method of assessing the evidence for a biomarker’s inclusion in a trial, 253 
however has some inherent limitations.  First, this method will not necessarily capture the entire 254 
evidence base upon which inclusion of the biomarker was justified, since the authors may not have 255 
provided a complete and accurate snapshot of the evidence they explored and used. Second, journal 256 
rules on the amount of references in a paper and word count restrictions could mean that the references 257 
included do not represent the totality of evidence used. Similar restrictions on references and word 258 
counts may limit the representation of the literature in protocols. 259 
 260 
8.1 Recommendations 261 
While the ideal level of evidence is a well-conducted meta-analysis/systematic review of good 262 
quality RCTs, including a rigorous assessment of their quality, this is not always available or feasible. 263 
In particular, where a biomarker is very new, there may be limited previous evidence to underpin its 264 
use. This evidence may take the form of case series or previous case studies. If this is the only evidence 265 
available, then this may be the ‘best’ evidence to justify including the biomarker in a trial. It would be 266 
important to consider, in such circumstances, whether the proposed RCT would be premature and that 267 
the science should first of all be allowed to mature.  268 
It may be that different standards of evidence may be necessary for different biomarker types 269 
[25,145]. For example, evidence standards could be based on risk, with biomarkers for lower risk 270 
applications requiring less evidence and regulatory oversight than those for high risk applications 271 
[145]. Recommendations could also be based on the disease being treated, similar to how orphan drugs 272 
for rare diseases are given accelerated approvals [146,147]. Biomarkers used for more serious 273 
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indications could be allowed to proceed to trial with less or lower quality evidence than biomarkers for 274 
less serious conditions. Novelty of the biomarker will also influence the extent of evidence available – 275 
for example a biomarker first utilised in 1980 is likely to have accumulated much more evidence than 276 
one first described in 2015.  277 
Further, some conditions have existing diagnostic or treatment guidance algorithms that do not 278 
use biomarkers but have good clinical utility. In these scenarios, adding a biomarker to the algorithm 279 
might provide a low value of information compared to a biomarker used in a condition where a good 280 
clinical algorithm is not available. Therefore, authors might consider prioritizing the development of 281 
biomarkers for conditions that do not have sufficient clinical prediction methods for diagnosis or 282 
guiding treatment.  283 
It is also important to ensure that genetic biomarkers are not subject to higher evidentiary 284 
requirements than other types of biomarkers. This ‘genetic exceptionalism’ and the higher burden of 285 
evidence for genetic tests has been shown to be a barrier to implementation [4,25,30,148]. Finally, 286 
biomarkers that are integral to a trial’s conduct require more evidence than biomarkers used on an 287 
exploratory basis [41].  288 
With these factors in mind, our recommendations for all biomarker-guided trials consist of two 289 
essentials (Figure 7).  290 
 291 
Figure 7 – our recommendations for evidence gathering prior to the start of a biomarker-guided trial, 292 
based on the findings of this review. 293 
 294 
- Systematic review before embarking on a trial 295 
We would recommend an initial systematic review is undertaken prior to the start of any trial. The 296 
Lancet journal now requires all research papers to include a ‘Research in Context’ panel that shows the 297 
evidence available prior to the study, and how the authors searched for this information [149]. This is 298 
an important step that should be considered by all journals and particularly any source funding a 299 
clinical trial. The search should be supplemented with evidence from other sources such as clinical 300 
guidelines and pilot data.  301 
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Regardless of the type of evidence identified in the systematic review, we recommend that the 302 
quality of that evidence is assessed when justifying including the biomarker, and we suggest that 303 
design-specific tools are used for this purpose (e.g. the Cochrane Collaboration’s Risk of Bias tool for 304 
RCTs) [150]. Several study type-specific methods for doing this are available [131,150-154] and have 305 
been reviewed by Zeng, et al. (2015) [155]. We additionally recommend the quality of pharmacogenetic 306 
studies is assessed using the guidelines proposed by Jorgensen and Williamson (2008) [156]. 307 
When synthesising evidence already existing from previous studies, it is also important to consider 308 
the age and ethnicities of the populations of the previous studies compared to the proposed trial’s 309 
population to ensure that the evidence is relevant. Many studies (94% in one review [157]) imply 310 
generalisability of results without acknowledging the differential effects of race and ethnicity.  311 
Differences in cancer incidence, stage at discovery [158], and mortality [159] have been found to be 312 
functions of race or ethnicity and it is imperative that trialists consider the ethnicity of the proposed 313 
trial population and to keep this in mind when evaluating the evidence relating to biomarker validity. 314 
Notably, a 2016 review found that 81% of participants in genome-wide association studies were white 315 
[160], and several studies have shown that non-white people are less likely to be clinical trial 316 
participants [157,161,162] and are less likely to access genetic testing services [163]. It is important, 317 
therefore, in a drive to reduce such inequalities, that the clinical utility of ethno-specific biomarkers are 318 
tested in trials recruiting participants from relevant ethnic backgrounds.  Similar considerations should 319 
be given to other factors known to contribute to health inequalities, including age, gender, and socio-320 
economic position. These factors are summarized by the PROGRESS-Plus acronym recommended by 321 
the Cochrane Public Health Group [164]. 322 
Further, if the systematic review reveals a sufficient number of previous RCTs or observational 323 
studies, authors should consider conducting a meta-analysis to assess the current evidence 324 
quantitatively. This would help ascertain whether there was sufficient uncertainty surrounding the 325 
current evidence to justify the planned RCT. An example of where this could have been implemented 326 
is in the fifth trial we examined [46]. Authors can also utilise funnel plots to examine any potential bias 327 
in the publication of included studies [165], and explore any heterogeneity between studies. 328 
- Guidelines are required 329 
Given the lack of standardisation across BM trials in terms of how inclusion of biomarkers are 330 
justified, we recommend that guidelines are developed to aid researchers in compiling and presenting 331 
evidence to justify their inclusions. This will not only ensure that sufficient evidence exists prior to 332 
embarking on a BM trial, thus avoiding waste of resources, but will also serve as a useful guide to those 333 
planning a BM trial and provide transparency in the trial report.  334 
The Clinical Pharmacogenetics Implementation Consortium (CPIC) provides guidelines for the 335 
implementation of pharmacogenetics [166]. The guidelines provide a grading of the level of evidence 336 
given in support of the biomarker’s implementation (‘high’, ‘moderate’ or ‘weak’) [167]. The CPIC 337 
levels are based on PharmGKB criteria (Figure 8), where the evidence for a gene-drug association is 338 
rated on a six-point scale between 1A (guidelines endorsed by a medical society or major health system) 339 
to 4 (in vitro, case study, or nonsignificant study evidence) [29]. This scale is based on ‘clinical 340 
annotations’ obtained from PubMed, produced by combining and summarising associations from 341 
several publications. These clinical annotations are then given a ‘level of evidence’ score based on 342 
replication of the association, P-value, and odds ratio. The score is determined by PharmGKB curators 343 
[29]. 344 
 345 
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 346 
Figure 8 – Guidelines of the Clinical Pharmacogenetics Implementation Consortium (CPIC) for the 347 
grading of biomarker evidence, based on the PharmGKB evidence criteria [29,168]. 348 
 349 
Whilst these guidelines are for implementation of biomarkers into clinical practice in a patient who 350 
has a known genotype, a similar approach could be developed for justification of use in a RCT. We 351 
located one paper that discussed the incorporation of biomarkers into early phase clinical trials [41],  352 
but we recommend that this needs to contribute to the formation of formal guidelines for BM trials 353 
similar to CPIC guidelines for biomarker implementation. 354 
Finally, the conclusions and recommendations above are based on the assumption that a BM trial 355 
is indeed required. It is possible that when compiling the evidence to justify inclusion of a biomarker 356 
in a trial that it is so overwhelmingly in favour of the biomarker’s clinical utility that it may be unethical 357 
to restrict its use to a randomised trial. This loss of clinical equipoise is something important to consider 358 
and indeed clinical implementation may be recommended and accepted without the need for a BM trial 359 
in such cases.  360 
 361 
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